Event Details

Registration for this event is now closed.

Immunotherapy has revolutionized cancer treatment. With the accomplishment of First-in-Human trials, a steady increase in new candidate drug approvals, and a substantial pipeline of drugs in clinical and preclinical testing, modulation of the immune system has become a clinical reality. Yet, many open research questions need to be addressed before immune targeting will become routine therapy. This panel will discuss the promise of cancer immunotherapy, challenges, and rational design approaches for delivering therapeutics to maximize the impact of this powerful treatment.


Michael Aberman ’93, President and CEO, Quentis Therapeutics, Inc.
Lance Collins, Joseph Silbert Dean of Engineering
Marjolein van der Meulen, James M. and Marsh McCormick Director of Biomedical Engineering, Swanson Professor of Biomedical Engineering
Ankur Singh, Assistant Professor, Sibley School of Mechanical and Aerospace Engineering and the Meinig School of Biomedical Engineering

5:00 PM Doors Open
5:30 PM Panel Discussion
6:30 PM Networking Reception
7:30 PM Program Concludes